About hMPV and PIV3 Vaccine Research
hMPV (human metapneumovirus) and PIV3 (parainfluenza virus 3) are respiratory viruses that can cause severe respiratory infections, especially in young children and older adults. These viruses are major contributors to respiratory illnesses, including bronchiolitis and pneumonia. Due to the significant impact they have on public health, there is a critical need for research focused on developing vaccines for hMPV and PIV3. By studying these viruses and developing effective vaccines, scientists aim to protect individuals at risk, reduce the spread of these infections, and prevent severe respiratory illnesses. This research is essential in improving public health outcomes and ensuring the well-being of vulnerable populations, particularly young children and older adults.
Why Participate
You can help advance medicine by joining a clinical trial at Velocity, and you may also:
- Learn about potential new medicines in development
- Get study-related medical exams at no cost
- Receive compensation for participating (available amounts may differ for each study)
After you submit your information, a Velocity enrollment specialist will contact you. Together, we’ll review studies that might be right for you and answer your questions.
Health insurance is NOT required to join. There is never an obligation to participate — we’re here to help you make the best decision.
For more information about currently enrolling research studies, complete the form on this page or select a location below to get in touch with a Velocity enrollment specialist.
